Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer

Enzalutamide, approved by the United States Food and Drug Administration in 2018 for the management of metastatic castration-resistant prostate cancer (CRPC), is an androgen receptor (AR) inhibitor. It blocks androgen binding to the AR, AR nuclear translocation, and AR-mediated DNA binding. Unfortun...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Biol Chem
Main Authors: Bai, Yunfeng, Zhang, Zhuangzhuang, Cheng, Lijun, Wang, Ruixin, Chen, Xiaoliang, Kong, Yifan, Feng, Feng, Ahmad, Nihal, Li, Lang, Liu, Xiaoqi
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Biochemistry and Molecular Biology 2019
Assuntos:
Signal Transduction
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6597805/
https://ncbi.nlm.nih.gov/pubmed/31085587
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.RA119.008152
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados